Valion Bio Announces That The Pentagon's Armed Forces Radiobiology Research Institute And National Institute of Allergy and Infectious Diseases Completed Their Design Of Survival Efficacy Protocol To Evaluate The Company's Entolimod To Treat Gastrointestinal Acute Radiation Syndrome